Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Despite the absence of detailed operational updates, strategic initiatives, and return plans, the financial performance was strong, with significant growth in revenue, operating profit, and EPS. The raised EPS guidance further supports a positive outlook. The lack of negative sentiment in the Q&A indicates no major concerns. These factors suggest a positive stock price movement.
Revenue Revenue for Q4 2026 was $68.4 billion, representing a 7% increase year-over-year. This growth was driven by strong performance in the U.S. Pharmaceutical segment and increased specialty drug volumes.
Operating Profit Operating profit for Q4 2026 was $1.2 billion, up 5% year-over-year. The increase was attributed to operational efficiencies and cost management initiatives.
Earnings Per Share (EPS) Adjusted EPS for Q4 2026 was $7.15, reflecting a 10% increase compared to the prior year. This was due to higher revenue and improved operating margins.
Cash Flow from Operations Cash flow from operations for the fiscal year 2026 was $4.5 billion, a 12% increase year-over-year. The improvement was driven by better working capital management and higher earnings.
The selected topic was not discussed during the call.
Forward-looking statements: Potential risks associated with forecasts about McKesson's operations and future results, as highlighted in the cautionary statements and risk factors section of SEC filings.
The selected topic was not discussed during the call.
The selected topic was not discussed during the call.
Despite the absence of detailed operational updates, strategic initiatives, and return plans, the financial performance was strong, with significant growth in revenue, operating profit, and EPS. The raised EPS guidance further supports a positive outlook. The lack of negative sentiment in the Q&A indicates no major concerns. These factors suggest a positive stock price movement.
The earnings call reveals strong financial performance, with raised guidance for EPS and revenue growth, alongside significant operating profit growth across segments. The Q&A highlights management's strategic investments in technology and automation, contributing to operational efficiency and margin improvements. Despite some lack of clarity on fiscal 2027 guidance, the overall sentiment is positive due to strong organic growth, strategic acquisitions, and positive market trends, suggesting a likely stock price increase in the near term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.